WR-2721: Inhibitor of cisplatin-induced micronuclei

Teratogenesis Carcinogenesis and Mutagenesis

Volumn 20, Issue 6, 2000, Pages 349-356

  Mazur, Lidia ^a   Czyewska, Agnieszka ^a   Augustynek, Anna ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

'Delayed apoptosis'; Chemoprotection; cis Diamminedichloroplatinum II ; Erythropoietic system; Geno and cyto toxicity; Micronuclei; S 2 3 aminopropylamino ethyl phosphorothioi c acid

Indexed keywords

AMIFOSTINE; CISPLATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE MARROW; CHEMOPROPHYLAXIS; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; ERYTHROCYTE; ERYTHROID PRECURSOR CELL; GENOTOXICITY; MALE; MICRONUCLEUS; NONHUMAN; PRIORITY JOURNAL; RAT;

AMIFOSTINE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE MARROW; CISPLATIN; ERYTHROCYTES; MALE; MICE; MICRONUCLEI, CHROMOSOME-DEFECTIVE;

ANIMALIA; LONCHOCARPUS GLAUCIFOLIUS;

EID: 0033695793     PISSN: 02703211     EISSN: None     Source Type: Journal    
DOI: 10.1002/1520-6866(2000)20:6<349::AID-TCM4>3.0.CO;2-E     Document Type: Article

References (35)

1. Interaction of platinum antitumor compounds with DNA
2. Genetic activity profiles of anticancer drugs
3. The clinical use of mutagenic anticancer drugs
4. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia
5. Similarity of apoptosis induction by 2-chlorodeoxyadenosine and cisplatin in human mononuclear blood cells
6. Chemotherapy-induced apoptosis
7. The in vivo micronucleus assay in mammalian bone marrow and peripheral blood: A report of the U.S. Environmental Protection Agency Gene-Tox Program
8. Micronucleus assay
9. Methods in analysis of apoptosis and cell necrosis
10. Apoptoza w uldadzie hemopoetycznym
11. Amifostine: Potential for clinically useful cytoprotection
12. Future development of Amifostine in cancer treatment
13. Reducing the toxicity of anticancer therapy: New strategies
14. Chemoprotection in anticancer therapy: The emerging role of Amifostine (WR-2721)
15. Protection of normal tissues from radiation and cytotoxic therapy: The development of Amifostine
16. Clinical trials of WR-2721 and cis-platinum
17. Biochemical modification of the toxicity and the anti-tumour effects of 5-fluorouracil and cis-platinum by WR-2721 in mice
18. Effect of WR-2721 on the toxicity and antitumor activity of the combination of carboplatin and 5-fluorouracil
19. WR-2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: A molecular approach
20. Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by Amifostine (Ethyol): Preclinical aspects
21. Amifostine: A review ot its pharmacodynamic and pharmacokinetics properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector
22. Amifostine in reducing cisplatin toxicity
23. Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy
24. Protection of normal tissue from the cytotoxic effects of chemotherapy by Amifostine (Ethyol): Clinical experiences
25. Reduced glutathione and S-acetylglutathione as selective apoptosis-inducing agents in cancer therapy
26. Involvement of intracellular glutathione in induction of apoptosis by cisplatin in a human pharyngeal carcinoma cell line
27. Cisplatin inhibits synthesis of ribosomal RNA in vivo
28. Immunocytochemical analysis of cisplatin-induced platinum-DNA adducts with double-fluorescende video microscopy
29. How does cisplatin alter DNA structure? A molecular mechanics study on double-stranded oligonucleotides
30. Solution structure of a cisplatin-induced DNA interstrand cross-link
31. Pharmacokinetics profile of Amifostine
32. Amifostine (Ethyol): Pharmacokinetics and pharmacodynamic effects in vivo
33. Exploration of platinum-based dose-intensive chemotherapy strategies with Amifostine (Ethyol)
34. Pharmacokinetics of cisplatin with and without Amifostine in tumor-beating nude mice
35. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by Amifostine